HHS Message On Value-Based Drug Pricing Complicated But Themes Emerging
Executive Summary
US government involvement in value assessments for prescription drugs and the benefits of outcomes-based contracting in lowering drug prices are among the issues being discussed.
You may also be interested in...
Gottlieb Shifts From Regulatory To Reimbursement Focus In One Of First Post-Commissioner Appearances
CAR-T reimbursement is concern for former US FDA commissioner Scott Gottlieb in speech at the National Press Club.
Rx Importation: Califf's Switch Means US FDA Commissioners No Longer Uniformly Opposed
In JAMA editorial, former FDA chief supports drug importation under narrow circumstances as a way to reduce drug prices, marking a shift from his previous stance on the issue and that of other past agency heads. Essay, co-authored by former CMS Acting Administrator Andy Slavitt, calls importation "a workaround born of desperation."
Brilinta Value-Based Contract With UPMC Incorporates Two-Sided Risk
AstraZeneca and UPMC Health Plan have signed a value-based contract for Brilinta linked to cardiovascular outcomes, with UPMC agreeing to pay more if the drug outperforms expectations.